Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

about

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

Item

http://www.wikidata.org/entity/Q59129976

description

im Dezember 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2018

@uk

name

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@en

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@nl

type

Item

label

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@en

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@nl

prefLabel

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@en

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@nl

P1476

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

@en

P2093

A Jacobs

http://www.w3.org/2001/XMLSchema#string

H K Surks

http://www.w3.org/2001/XMLSchema#string

M A Panzara

http://www.w3.org/2001/XMLSchema#string

S Richards

http://www.w3.org/2001/XMLSchema#string

Z Li

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Assessing the Immunogenicity of Biopharmaceuticals

Alemtuzumab for the treatment of multiple sclerosis

Reshaping human antibodies for therapy

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Monoclonal antibodies in multiple sclerosis treatment: current and future steps.

Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.

The CD52 antigen and development of the CAMPATH antibodies.

P304

295-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CEI.13208

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

194

http://www.w3.org/2001/XMLSchema#string

P577

2018-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30144037

http://www.w3.org/2001/XMLSchema#string

P921

immunology

Farmakologi

P932

6231011

http://www.w3.org/2001/XMLSchema#string